

COCO_LATE - Clinical events occurring within 6 months of SARS-COV-2 infection: multicentre cohort

Head :ROBINEAU Olivier

Last update : 05/06/2021 | Version : 1 | ID : 73902

General

Identification

Detailed name Clinical events occurring within 6 months of SARS-COV-2 infection: multicentre cohort

Sign or acronym COCO_LATE

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL MR01, favorable opinion CPP

General Aspects

Medical area Infectious diseases
Psychology and psychiatry

Study in connection with Covid-19 Yes

Scientific investigator(s) (Contact)

Name of the director ROBINEAU

Surname Olivier

Collaborations

Participation in projects, networks and consortia Yes

Funding

Funding status Public

Governance of the database

Sponsor(s) or organisation(s) responsible Tourcoing Hospital

Organisation status Public

Presence of scientific or steering committees

Yes

Additional contact

Name of the contact

TREHOUX

Surname

Solange

Email

recherche@ch-tourcoing.fr

Main features

Type of database

Type of database

Others

Study databases (details)

Cohort study

Database objective

Main objective

Describe, over time, the symptoms presented by patients reporting persistent symptoms (more than two months after onset) or onset of symptoms more than 3 weeks after the beginning of symptomatic SARS-CoV-2 (COVID-19) infection evidenced by laboratory tests.

Inclusion criteria

1- History of symptomatic SARS-CoV-2 infection defined by:
A positive RT-PCR result for SARS-CoV-2 OR positive SARS-CoV-2 serology combined with at least one event:
- Anosmia occurring after February 2020
- OR CT scan consistent with COVID-19
- OR ? 2 symptoms coinciding with the virology sample, including: asthenia, cough, dyspnoea, fever, myalgia, dysgeusia, diarrhoea AND not present prior to diagnosis
2- AND persistence of at least one symptom present in the first 3 weeks of COVID-19, more than 8 weeks after the first COVID symptoms OR late onset of at least one new symptom at least 3 weeks and not more than 6 months after the first symptoms of SARS-CoV-2 infection
3- First symptoms within the past 6 months on the date of inclusion
4- Beneficiary of a health insurance scheme or the state welfare scheme
5- Having signed an informed consent form at inclusion

Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	B99-B99 - Other infectious diseases
Gender	Male Woman
Geography area	National
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[500-1000[individuals
Data	
Database activity	Current data collection
Type of data collected	Clinical data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Presence of a biobank	Yes
Contents of biobank	Serum Plasma
Procedures	
Followed pathology	
Promotion and access	
Promotion	

